The Global Clinical Development Group of a large Pharmaceutical Company asked for help with European patient recruitment/retention to their Global Phase II Study.
Their study was suffering from a significant lack of patient recruitment in Europe and those patients who were being recruited were not being retained - only 18 out of the 100 European patients had been recruited.
The Company was preparing for the trial recruitment to be stopped in Europe and moved elsewhere with a subsequent major delay in trial completion.
daCRO was asked investigate cause.
By acting as a patient recruitment accelerator we enabled CRO to achieve targeted patient enrolment in Europe within 6 months.
“ The use of academic networks and the way they helped us and our CRO to achieve patient enrolment has led me to re-assess how I operate ”